Daily aspirin cuts bowel cancer risk

Scientists who analysed data on more than 14,000 patients found that taking the painkiller over several years reduced the chances of developing Britain's third most common cancer by a quarter.

It also cut the number of deaths from the disease by more than a third.

The effective doses of the drug were relatively low, ranging from 75 to 300 milligrams.

Previous research had suggested regular high doses of more than 500 milligrams of aspirin can reduce bowel cancer rates.

But over-exposure to aspirin can lead to potentially dangerous side effects, such as internal bleeding and stomach ulcers.

The new study was the first to assess whether taking aspirin in lower doses had an impact on bowel cancer.

Researchers gathered data from four randomised aspirin trials conducted to investigate the prevention of artery disease.

On average, patients were men and women in their sixties who took the pill for six years.

Over a period of around 20 years, 391 of the trial participants, or 2.8 per cent, developed bowel cancer.

Aspirin was shown to reduce the risk of the disease by 24 per cent and cut death rates by 35 per cent.

The results are published today in The Lancet medical journal.

The study showed that aspirin's effect on bowel cancer was mainly due to its impact in the upper part of the large intestine.

Each year around 38,600 people in the UK are diagnosed with bowel cancer.